SLN: Silence Therapeutics Plc - ADR Company Profile & Statistics

Silence Therapeutics Plc - ADR Profile

About

Silence Therapeutics plc focuses on the discovery, development and delivery of novel RNA therapeutics in hematology, cardiovascular and other rare and metabolic indications. The Company's product candidate consist SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein and SLN500 for the treatment of complement-mediated diseases which are in clinical stage. Silence Therapeutics plc is based in London, the United Kingdom.

Info & Links

CEO

Iain Ross

Headquarters

12 HAMMERSMITH GROVE, OFFICE 205
LONDON, X0 W6 7AP, UNITED KINGDOM

Auditor

PricewaterhouseCoopers LLP

Share holders

1,259

Employees

Silence Therapeutics Plc - ADR Statistics

Valuation Measures

Market Capitalization²

249.87M

Enterprise Value

238.59M

Enterprise Value/EBITDA(ttm)

-2.64

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

439.39

Price to Book(mrq)

3.94

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

62.12%

Operating Margin(ttm)

-15615.03%

Profit Margin(ttm)

-20025.48%

Return on Equity(ttm)

-101.71%

Return on Invested Capital(ttm)

-101.55%

Return on Assets(ttm)

-55.53%

Income Statement

Revenue(ttm)

559.00K

Revenue Per Share(ttm)

0.01

Gross Profit(ttm)

344.00K

EBITDA(ttm)³

-90.52M

Net Income Available to Common(ttm)

-88.61M

Diluted EPS(ttm)

-1.87

Share Statistics

Beta (5Y Monthly)

1.32

52-Week Change

46.13%

S&P 500 52-Week Change

13.77%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

47.23M

Dividend Yield

0.00%

Float⁴

45.30M

% Held by Insiders

4.10%

% Held by Institutions

98.73%

Balance Sheet

Total Cash(mrq)

85.11M

Total Cash Per Share(mrq)

1.80

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

8.72%

Quick Ratio(mrq)

8.72%

Book Value Per Share(mrq)

1.32

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.32

Free Cash Flow(ytd)

-62.33M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

SLN

Silence Therapeutics Plc - ADR